Valeant Pharma's (VRX) Proposed Credit Amendment Will Improve Liquidity Position - Moody's

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. XENE
3. NUE
4. HUBS
5. RTB
6. ONON
7. AAPL
8. TRMD
9. ACN
10. AZN

Go back to Valeant Pharma's (VRX) Proposed Credit Amendment Will Improve Liquidity Position - Moody's

Big Valeant Pharma (VRX) Investors, Pershing Square's Ackman Met Ahead of Q2 Report -NYP

August 10, 2016 10:01 AM EDT

Large Valeant Pharmaceuticals (NYSE: VRX) investors were said to have met up with Pershing Square's Bill Ackman weeks before the company's Q2 release, which had it announce plans to reorganize and pay-down debt, according to the NYPost.

BofA... More

BTIG Remains Neutral on Valeant (VRX) Post-Q2; Sees Longer-than-Projected Path to Recovery

August 10, 2016 9:54 AM EDT

BTIG affirms Valeant Phama (NYSE: VRX) at Neutral following Q2 results from the company.

Analyst Timothy Chiang commented, While quarterly results were mixed, the Co. maintained its full year financial targets (which include revenues of $9.9 - $10.1B and EPS of $6.60 - $7.00). While... More

Valeant (VRX) PT Bumped to $22 at Piper Jaffray; Keeps Lowest Rating

August 10, 2016 7:04 AM EDT

Piper Jaffray analyst David Amsellem bumped his price target on Valeant Pharmaceuticals (NYSE: VRX) to $22.00 (from $19.00) but maintained an Underweight rating following results and reaffirmed guidance, which the analyst said may be overly optimistic.

Amsellem commented, "Valeant reported 2Q16 non-GAAP diluted EPS of $1.40 on revenue of $2.42B, lighter than Street... More